<DOC>
	<DOCNO>NCT01600976</DOCNO>
	<brief_summary>The purpose study determine whether pharmacokinetic ( body drug ) parameter telaprevir altered patient moderate hepatic impairment , compare pharmacokinetic parameter patient normal liver function , measure relative unbound plasma concentration telaprevir .</brief_summary>
	<brief_title>A Study Assess Safety Pharmacokinetics Telaprevir Patients With Hepatic Impairment</brief_title>
	<detailed_description>This Phase I , open-label ( people know identity intervention ) study investigate single dose steady state pharmacokinetics telaprevir patient moderate hepatic impairment , measure relative unbound plasma concentration telaprevir . In addition , small group patient severe hepatic impairment include characterize pharmacokinetics telaprevir function liver disease . In study 24 patient enrol . Based upon physical examination laboratory assessment , patient score classified hepatic function group basis Child-Pugh classification ( Classification base Child-Pugh score use assess prognosis chronic hepatic disease ) . A Child-Pugh score 7 9 consider Child-Pugh category B ( CPB ) indicative moderate liver function impairment ; Child-Pugh score 10 great consider Child Pugh category C ( CPC ) , indicative severe liver impairment . Hepatic function group consist Group 1 : 10 patient moderate hepatic impairment ( CPB 7 9 ] ) ; Group 2 : 10 healthy control patient normal hepatic function . Each healthy control patient match patient Group 1 respect sex , age ( +5 year -5 year ) body mass index ( BMI ) ( +15 % -15 % ) ; Group 3 : 4 patient severe hepatic impairment ( CPC [ limit Child Pugh score 10 12 ] ) . Safety tolerability evaluation include adverse event , clinical laboratory test , 12-lead electrocardiogram , vital sign physical examination record throughout study period .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>For Group 1 : Moderate liver function impairment ( Child Pugh score 7 9 ) History hepatic disease , hepatitis B , previous hepatitis C , alcoholic liver disease , autoimmune hepatitis , nonalcoholic fatty liver disease , hereditary/metabolic , cryptogenic , Consistent disease process hepatic impairment associate symptom For Group 2 : Matched patient moderate hepatic impairment regard sex , age ( ± 5 year ) , BMI ( ± 15 % ) healthy basis medical evaluation reveals absence clinically relevant abnormality For Group 3 : Severe liver function impairment ( limited Child Pugh score 10 12 ) Hepatic impairment due different etiology hepatitis B , previous hepatitis C , alcoholic liver disease , autoimmune hepatitis , nonalcoholic fatty liver disease , hereditary/metabolic , cryptogenic , Consistent disease process hepatic impairment associate symptom For Group 1 3 : Has acute infectious hepatitis Has grade 3 4 encephalopathy Has grade 3 4 creatinine elevation Is active candidate liver transplantation Has variceal bleed spontaneous bacterial peritonitis For Group 1 : Has portacaval shunt transjugular intrahepatic portosystemic shunt For Group 2 : Has acute hepatitis A hepatitis B hepatitis C infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Telaprevir</keyword>
	<keyword>VX-950</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Unbound plasma concentration</keyword>
	<keyword>Child-Pugh score</keyword>
</DOC>